Top in cardiology: FDA OKs gout drug to reduce CV events; studies support SGLT2 inhibitors
Click Here to Manage Email Alerts
A 0.5 mg dose of colchicine, a drug commonly used for conditions such as gout, was recently approved by the FDA to prevent cardiovascular events in patients with residual inflammatory risk.
It is the first anti-inflammatory agent to be approved as an atheroprotective CV treatment, according to a press release from the manufacturer, and is expected to be available later this year. News of the approval was the top story in cardiology last week.
Another top story was about a meta-analysis that showed that SGLT2 inhibitors consistently reduced the risk for CV death and heart failure hospitalizations in high-risk patients. The study aimed to fill a knowledge gap about the efficacy of SGLT2 inhibitors in patients with varying multimorbidity, which individual trials did not sufficiently assess.
Read these and more top stories in cardiology below:
FDA approves CV version of colchicine for patients with residual inflammatory risk
Agepha Pharma announced that the FDA approved a 0.5 mg dose of colchicine for reduction of CV events in patients with atherosclerotic CVD or multiple CV risk factors who have residual inflammatory risk. Read more.
Meta-analysis confirms benefits of SGLT2 inhibitors in various high-risk populations
SGLT2 inhibitors reduce risk for CV death and heart failure events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology. Read more.
‘Pray’ and ‘hope’: Assessing social media response to Damar Hamlin’s sudden cardiac arrest
An analysis of social media reactions after the televised collapse of Damar Hamlin suggests many people do not see an active role for themselves after witnessing a sudden cardiac arrest, prompting a call for public awareness campaigns. Read more.
In new book, Singh explains how technology can shape future of health care
Healio | Cardiology Today Editorial Board Member Jagmeet P. Singh, MD, DPhil, FACC, FHRS, and some of his patients were profoundly affected by the COVID-19 pandemic. That got him thinking about the sustainability of the health care system. Read more.
Chat-based AI models accurately answer questions about atrial fibrillation from patients but not physicians
ChatGPT and Bing AI provided mostly accurate responses to patients’ commonly asked questions about atrial fibrillation, but they appear not suitable to aid clinician-level decision-making, researchers reported. Read more.